Jacobson & Schmitt Advisors LLC Sells 6,794 Shares of IDEXX Laboratories, Inc. $IDXX

Jacobson & Schmitt Advisors LLC cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,105 shares of the company’s stock after selling 6,794 shares during the quarter. IDEXX Laboratories comprises about 2.2% of Jacobson & Schmitt Advisors LLC’s holdings, making the stock its 24th largest position. Jacobson & Schmitt Advisors LLC’s holdings in IDEXX Laboratories were worth $12,845,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its stake in IDEXX Laboratories by 156.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after purchasing an additional 884,808 shares during the period. Generation Investment Management LLP purchased a new stake in shares of IDEXX Laboratories in the second quarter worth about $304,277,000. Norges Bank bought a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $221,955,000. JPMorgan Chase & Co. grew its stake in IDEXX Laboratories by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after acquiring an additional 326,348 shares in the last quarter. Finally, Schroder Investment Management Group increased its holdings in IDEXX Laboratories by 295.1% during the 2nd quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock worth $169,368,000 after acquiring an additional 235,863 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president directly owned 9,823 shares in the company, valued at $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael G. Erickson sold 5,371 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the sale, the executive vice president owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 18,180 shares of company stock worth $11,626,996 over the last ninety days. Insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

IDXX has been the subject of several analyst reports. JPMorgan Chase & Co. raised their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 7th. Barclays reduced their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Piper Sandler decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Trading Up 4.2%

NASDAQ IDXX opened at $649.35 on Wednesday. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The stock’s 50-day simple moving average is $675.31 and its two-hundred day simple moving average is $669.07. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The company has a market capitalization of $51.70 billion, a price-to-earnings ratio of 49.68, a PEG ratio of 3.79 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.